Relationship between the pharmacological and biochemical properties of a monoamine oxidase inhibitor preferentially affecting 5-hydroxytryptamine oxidation.
D000818:Animals; D001923:Brain Chemistry; D066298:In Vitro Techniques; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D009638:Norepinephrine / Q000032:analysis; D010624:Phenelzine / Q000008:administration & dosage; D011437:Propylamines / Q000494:pharmacology*; D051381:Rats; D012701:Serotonin / Q000032:analysis / Q000378:metabolism*; D013747:Tetrabenazine / Q000494:pharmacology; D014191:Tranylcypromine / Q000494:pharmacology; D014439:Tyramine / Q000378:metabolism
D008996:Monoamine Oxidase Inhibitors; D011437:Propylamines; D012701:Serotonin; D014191:Tranylcypromine; D010624:Phenelzine; D009638:Norepinephrine; D014439:Tyramine; D013747:Tetrabenazine